Scan evidence products

Evidence products prepared or updated with funding from COVID-END in Canada can be accessed below. These evidence products are shared through our twice-a-month Canadian spotlights and through many of our dissemination partners. If you want to receive an email containing hyperlinks to our Canadian (and global) spotlights twice a month, subscribe here.

Title/question (if in progress) Synthesis product type (product #) Status Date of last search (and publication)
What went well and what could have gone better in the COVID-19 response in Canada, as well as what will need to go well in future given any available foresight work being conducted?
Living evidence profile (LEP 4.1)  In progress  

What is the best-available evidence about the management of long COVID symptoms and care models for long COVID patients?

Response based on existing resources (Response 10)  Complete 2021-05-07 (published 2021-05-11) 

What is known about how schools (K-12) and post-secondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase?

Living evidence profile (3.1)
Complete 2021-05-07 (published 2021-05-11)

What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern?

  • Report (6.4)
  • Past versions: 6.3 (30 April 2021); 6.2 (23 April 2021)
Living evidence synthesis (LES 6.4)
Complete 2021-05-07

How can vaccine acceptance and uptake be supported among equity seeking groups?

Response based on existing resources (Response 5)
Complete  2021-05-04 

What are the implications of SARS-CoV-2 variants for public-health measures and health-system arrangements?

Living evidence synthesis (5.1) Complete 2021-04-07 (published 2021-05-03)

How can behavioural-science thinking help to support messaging to and broader supports for citizens, particularly those drawn from equity-seeking groups, to encourage them to be vaccinated

Living evidence synthesis (LES 4.1) Complete 2021-04-30
How can we support crisis management and renewal in long-term care? Living evidence profile (LEP 2.3) Complete 2021-04-26
What is known about anticipated COVID-19 vaccine roll-out elements? Living evidence profile (LEP 1.6) Complete 2021-04-20

What is known about the effects, communication, implementation and enforcement of nighttime curfews on COVID-19 infections?

Response based on existing resources (Response 9)  Complete 2021-04-14

What is the best-available evidence about the use of colchicine and ivermectin for COVID-19?

Response based on existing resources (Response 8)
Complete 2021-04-09 

What is the best-available evidence about the impact of COVID-19 on developing coagulopathies?

Response based on existing resources (Response 7)
Complete 2021-04-08

What is known about the development, implementation, and funding of long COVID-19 clinics across jurisdictions?

Response based on existing resources (Response 6)
Complete 2021-04-06 
How can behavioural-science thinking help to support messaging to and broader supports for healthcare workers to encourage them to: a) be vaccinated; and b) address vaccine hesitancy and enable vaccine uptake among their patients and citizens more generally, particularly those drawn from equity-seeking groups Living evidence synthesis (LES 3.1)
Complete 2021-03-31 

What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern?

Response based on existing resources (Response 4)
Complete 2021-03-26
When and in what order can COVID-19-related public-health measures be lifted (or stringency be reduced) as vaccination rates and seasonal temperatures increase? 
  • Plain-language summary (English | French)
  • Report
Rapid evidence profile (REP #26) Complete 2021-03-17 (published 2021-03-18)
Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals and, if so, how large is the risk compared to unvaccinated people and those infected with SARS-CoV-2 variants? Living evidence synthesis (LES 1.2)  Complete 2021-03-11 (published 2021-03-12) 
What are the transmission characteristics of SARS-CoV-2 variants of concern? 
  • Plain-language summary (English | French)
  • Report
  • Brief
Living evidence synthesis (LES 2.1) Complete 2021-03-01 (published 2021-03-17)
What factors affect health workers’ attitudes toward vaccination uptake and what strategies have been successful in increasing vaccination among health workers? Response based on existing resources (Response 3)  Complete Last updated 2021-02-04
Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals and, if so, how large is the risk compared to unvaccinated people? Response based on existing resources (Response 2) Complete Last updated 2021-02-04
What do we know from both research and jurisdictional scans about prioritizing vaccination of asymptomatic residents in a long-term care home with an outbreak? Rapid evidence profile (REP #25) Complete 2021-01-19 (published 2021-01-20)
How can we best leverage existing resources to provide evidence-based advice on COVID-19 therapeutics and issue guidance statements to inform decision makers and healthcare professionals on the use of pharmaceuticals for the treatment or chemoprophylaxis of COVID-19? Response based on existing resources (Response 1) Complete Last updated 2020-12-20

Our evidence products can take many forms:

  • response based on existing resources
  • one-off rapid evidence profile or rapid synthesis
  • living evidence profile or living evidence synthesis that is updated regularly.

Our evidence profiles and evidence syntheses vary in:

  • the effort that goes into them, which we measure in the number of hours or days that a very large team of highly experienced staff devote exclusively to the task (e.g., four hours to three days for evidence profiles and for updates to living evidence profiles; five to ten days for rapid syntheses and for updates to living evidence syntheses)
  • the type of best evidence they include and whether they also include a jurisdictional scan.

Below we provide examples of how these evidence products can vary.

Product type Best evidence Jurisdictional scan 
Rapid evidence profile (four hours) Profile of existing evidence syntheses
1-2 provinces and 1-2 countries
Rapid evidence profile (1 day)
Same but with more decision-relevant information extracted and quality rating of evidence syntheses
3-4 provinces and 3-4 countries
Rapid evidence profile (2 days)
Same but with even more decision-relevant information extracted
5-6 provinces and 5-6 countries
Rapid evidence profile (3 days)
Same plus profile of singles studies
All Canadian jurisdictions and up to 10 countries
Rapid review – Scoping (5-10 days)
Inventory of syntheses and single studies
No
Rapid review – Overview (5-10 days)
Overview of syntheses with quality ratings
No
Rapid review – Synthesis (5-10 days)
Synthesis of single studies with risk-of-bias assessment
No